Bioactivity Studies of β-Lactam Derived Polycyclic Fused Pyrroli-Dine/Pyrrolizidine Derivatives in Dentistry: In Vitro, In Vivo and In Silico Studies
作者:Gowri Meiyazhagan、Rajesh Raju、Sofi Beaula Winfred、Bhavani Mannivanan、Hemadev Bhoopalan、Venkatesh Shankar、Sathiya Sekar、Deepa Parvathi Venkatachalam、Ravishankar Pitani、Venkateshbabu Nagendrababu、Malini Thaiman、Kandaswamy Devivanayagam、Jeyakanthan Jayaraman、Raghunathan Ragavachary、Ganesh Venkatraman
DOI:10.1371/journal.pone.0131433
日期:——
Cytometry by PI up-take. Compound 3 treated E. faecalis showed ROS generation and loss of membrane integrity was quantified by flow cytometry. Compound 3 was also found to be active against resistant E. faecalis strains isolated from failed root canal treatment cases. Further, compound 3 was found to be hemocompatible, not cytotoxic to normal mammalian NIH 3T3 cells and non mutagenic. It was concluded that
通过1,3-偶极环加成反应合成的β-内酰胺衍生的多环稠合吡咯烷/吡咯烷核苷衍生物的抗菌活性针对与牙齿感染有关的微生物进行了评估。筛选了十五种化合物;其中化合物3在离体牙本质小管模型和体内小鼠感染模型中显示出有效的抗菌活性。在计算机对接研究中显示了对青霉素结合蛋白的更大亲和力。在扫描电子显微镜(SEM)下观察到细胞损伤,其通过共聚焦激光扫描显微镜(CLSM)进一步证实,并通过流式细胞术通过PI摄取定量。化合物3处理的粪肠球菌显示了ROS的产生,并且通过流式细胞术定量了膜完整性的损失。还发现化合物3对抗性E具有活性。从失败的根管治疗案例中分离出的粪便菌株。此外,发现化合物3具有血液相容性,对正常的哺乳动物NIH 3T3细胞没有细胞毒性,并且不具有致突变性。结论是,β-内酰胺化合物3对参与根管感染的粪便大肠杆菌显示出有希望的抗菌活性,并阐明了其作用机理。这项研究的结果可能进一步涉及在牙科领域中应用的有效抗菌药物的开发。